CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies

NCT04700319 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

CAR

Interventions

DRUG: CD19/CD20 CAR-T cell infusion

Sponsor

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Collaborators

[object Object]